Correction to: Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.

Drug Saf

Department of Biomedical Sciences and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen N, Denmark.

Published: July 2019

In the original publication of this article, the following correction should be noted in Table 1.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40264-019-00830-5DOI Listing

Publication Analysis

Top Keywords

correction benefit-risk
4
benefit-risk assessment
4
assessment obesity
4
obesity drugs
4
drugs focus
4
focus glucagon-like
4
glucagon-like peptide-1
4
peptide-1 receptor
4
receptor agonists
4
agonists original
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!